lobaplatin (D19466) / COSCIENS Biopharma - LARVOL DELTA

Construction of a Prognostic Model Based on Insulin Resistance-Related Genes to Predict TACE Response and Identification of PD-98059 as a Potential Therapeutic Agent. (PubMed, J Hepatocell Carcinoma) - "Cell experiments confirmed that PD-98059 synergistically enhanced the inhibitory effect of lobaplatin on HCC cell proliferation. The insulin resistance model tailored for TACE effectively predicts patient prognosis. Via the effect of MEK inhibitor PD-98059, the efficacy of TACE in patients can be improved."

Journal • Diabetes • Hepatocellular Cancer • Liver Cancer • Metabolic Disorders • Oncology • Solid Tumor • DUSP9 • SERPINE1

A phase I dose-escalation study of Lobaplatin combined with paclitaxel in platinum-sensitive recurrent ovarian epithelial carcinoma: preliminary safety and tolerability supporting clinical trial dosing. (PubMed, Gynecol Oncol Rep) - "Observed antitumor activity in this small phase I cohort are exploratory and warrant confirmation in larger, appropriately powered studies. A Phase I Dose-Escalation Study of Lobaplatin Combined with Paclitaxel in Platinum-Sensitive Recurrent Ovarian Epithelial Carcinoma: Preliminary Safety and Tolerability Supporting Clinical Trial Dosing."

Journal • P1 data • Platinum sensitive • Neutropenia • Ovarian Cancer • Pain • Solid Tumor • Thrombocytopenia

Comprehensive diagnosis and individualized treatment of multiple primary lung cancer: A case report. (PubMed, Exp Ther Med) - "The patient was treated with a two-stage surgery (first surgery on the left lung, second surgery on the right lung) according to the protocol, coupled with adjuvant chemotherapy (700 mg pemetrexed combined with 45 mg lobaplatin) between surgeries. In addition, an individualized treatment design would be more beneficial to patients with MPLC, especially those with a large number of lesions in both lungs. The present study reports a case of the diagnosis and individualized treatment of MPLC with multiple lesions in both lungs, which provides a reference for the diagnosis and treatment of similar patients."

Journal • Lung Cancer • Oncology • Solid Tumor

Influence of gemcitabine combined with lobaplatin interventional embolization on vaginal flora and biofilm formation in patients with advanced cervical cancer. (PubMed, Afr J Reprod Health) - "GEM+LOB interventional embolization not only improved treatment efficacy and survival prognosis in patients with locally advanced cervical cancer but also modulated vaginal microbiota imbalance and inhibited biofilm formation of Gv. These findings provide a new theoretical basis for optimizing clinical treatment strategies for cervical cancer and exploring the relationship between cancer therapy and vaginal microecological balance."

Clinical • Journal • Cervical Cancer • Oncology • Solid Tumor • Vaginal Cancer

Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial. (PubMed, Nat Commun) - "The incidence of late toxic effects is similar between the therapy groups, except for grades 1-2 peripheral neuropathy (p = 0.033), grades 1-2 deafness/otitis (p = 0.021), and grades 1-2/3 nephrotoxicity (p = 0.005; p = 0.021), the incidence of which is greater in the cisplatin-based therapy group than in the lobaplatin-based therapy group. Our findings suggest that lobaplatin and fluorouracil induction chemotherapy plus lobaplatin-based concurrent chemoradiotherapy is an alternative doublet treatment strategy to cisplatin-based concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma."

Journal • P3 data • Nasopharyngeal Carcinoma • Oncology • Otorhinolaryngology • Pain • Solid Tumor

Efficacy and Safety of Iparomlimab and Tuvonralimab Combined with Albumin-bound Paclitaxel and Lobaplatin as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer：A Prospective, Multicenter, Single-Arm Study (ChiCTR) - P4 | N=67 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University

New P4 trial • Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

Safety and efficacy of hyperthermic intraperitoneal chemotherapy of lobaplatin after cytoreductive surgery for appendiceal mucinous neoplasm with PCI>=20: a prospective, single-arm, single-center clinical trial (ChiCTR) - P=N/A | N=47 | Not yet recruiting | Sponsor: Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University

New trial • Appendix Cancer • Oncology

Malignant mesothelioma in rare sites: two case reports. (PubMed, Front Oncol) - "Conversely, a 66-year-old male with MPM exhibited primary platinum resistance, progressing after first-line pemetrexed/lobaplatin and subsequent second-line chemotherapy. Peritoneal mesothelioma responded better to immuno-chemotherapy, while MPM showed platinum resistance. These contrasting disparate outcomes underscore that precise pathology and individualized treatment based on anatomic site are crucial, suggesting that malignant pleural and peritoneal mesothelioma may represent distinct clinical entities."

Journal • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Peritoneal Mesothelioma • Pleural Mesothelioma • Solid Tumor

Lobaplatin versus cisplatin in concurrent chemoradiotherapy for elderly cervical cancer: randomized controlled phase II study. (PubMed, J Gynecol Oncol) - "Lobaplatin-based CCRT demonstrates comparable efficacy to cisplatin in elderly cervical cancer patients, with superior renal safety and improved gastrointestinal tolerability, establishing it as a viable alternative for cisplatin-intolerant populations."

Journal • P2 data • Cervical Cancer • Hematological Disorders • Oncology • Solid Tumor • Thrombocytopenia

Real-world survival patterns and multimodal therapy utilization in small cell lung cancer: a retrospective cohort study in a Chinese countryside hospital. (PubMed, Front Oncol) - "Of 132 patients (64 LS-SCLC, 68 ES-SCLC), most received first-line platinum-etoposide regimens, with diminishing treatment continuity in later lines due to cumulative toxicities. Conversely, irinotecan-lobaplatin combinations provided limited benefit. Findings emphasize the need for personalized treatment sequencing and improved access to standardized multimodal care in rural healthcare settings."

Journal • Real-world evidence • Retrospective data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Pathological complete response to conversion therapy for lung adenocarcinoma with brain metastasis: a case report. (PubMed, Front Oncol) - "After multidisciplinary discussion, it was decided to administer targeted therapy with furmonertinib, chemotherapy with pemetrexed and lobaplatin, and immunotherapy with tislelizumab. For patients with metastatic advanced NSCLC, systemic treatment involving chemotherapy plus immunotherapy and targeted therapy is expected to become one of the options. Moreover, it is likely to achieve successful conversion surgery and further efficacy after combined therapy."

IO biomarker • Journal • Brain Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MAP2K1 • MAPK1 • PD-L1

Pt-seq unveils the genomic binding pattern of platinum-based drugs. (PubMed, Sci Adv) - "By using exo- and endonucleases to remove background, Pt-seq enables robust and sensitive profiling of binding sites for cisplatin, oxaliplatin, lobaplatin, and a Pt(IV) complex. On this basis, we demonstrated that ICR-191, an acridine orange compound capable of inducing G insertions, enhances cisplatin-DNA binding and sensitizes cells to cisplatin. Collectively, Pt-seq sensitively profiles Pt-DNA interactions and deepens our understanding of the genome-wide effect of chemotherapeutic drugs."

Journal • Oncology

The Efficacy and Safety of Lobaplatin vs. Cisplatin in Concurrent Chemoradiotherapy for Elderly Patients with Cervical Cancer: An Open-Label,Prospective Phase 2 Study (ASTRO 2025) - "Compared with cisplatin, lobaplatin has similar efficacy in the treatment of concurrent chemoradiotherapy for elderly patients with cervical cancer, with tolerable adverse reactions and lower upper gastrointestinal reaction and renal toxicity. It can be clinically recommended for elderly patients with cervical cancer who have renal insufficiency or intolerable gastrointestinal reactions."

Clinical • P2 data • Cervical Cancer • Oncology • Solid Tumor

Albumin-bound paclitaxel combined with lobaplatin using different administration methods in the treatment of cervical cancer: Study on the efficacy and its effect on immune function and inflammatory response. (PubMed, Pak J Med Sci) - "Albumin-bound paclitaxel combined with lobaplatin has a significant therapeutic effect for interventional chemoembolization of patients with cervical cancer. It may significantly improve the short-term and long-term clinical efficacy and immune function, and alleviate the inflammatory condition of cervical cancer patients."

Journal • Cervical Cancer • Oncology • Solid Tumor • IFNG • IL10 • TGFB1 • TNFA

Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis. (PubMed, Discov Oncol) - "Platinum-based anthracycline-free NAC regimens combined with taxanes appear to be both effective and well-tolerated in patients with TNBC. Nevertheless, in the absence of randomized controlled trials (RCTs) directly comparing this approach to anthracycline-based regimens, further investigation is warranted to substantiate these findings."

Journal • Retrospective data • Breast Cancer • Leukopenia • Neutropenia • Solid Tumor • Triple Negative Breast Cancer

Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer (clinicaltrials.gov) - P4 | N=468 | Not yet recruiting | Sponsor: Shandong Cancer Hospital and Institute

New P4 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

Choroidal metastasis as the first sign of small cell lung cancer: A case report. (PubMed, Oncol Lett) - "First-line chemotherapy regimens consisted of etoposide and nedaplatin, while second-line regimens consisted of liposomal paclitaxel combined with lobaplatin. Furthermore, palliative care, psychological support and socioeconomic assistance are key to the quality of life of patients. Adoption of a patient-centered approach to provide comfort can also optimize treatment outcomes and improve the quality of life of patients."

Journal • Lung Cancer • Oncology • Palliative care • Respiratory Diseases • Retinal Disorders • Small Cell Lung Cancer • Solid Tumor

Main results of a randomized controlled trial (RNPLS-01): efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant therapy for advanced gastric cancer. (PubMed, Int J Surg) - "Ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 significantly enhances the pCR rate and ORR in neoadjuvant therapy of locally advanced gastric cancer patients, while maintaining an acceptable safety profile."

Journal • Gastric Cancer • Oncology • Solid Tumor • KDR

DFT and Molecular Docking Study of HA-Conjugated SWCNTs for CD44-Targeted Delivery of Platinum-Based Chemotherapeutics. (PubMed, Pharmaceuticals (Basel)) - " This study compares non-functionalized (DDS1) versus HA-conjugated single-walled carbon nanotubes (DDS2) for encapsulation stability and CD44 binding of Cisplatin, Carboplatin, and Lobaplatin. Docking scores indicate that HA conjugation notably strengthens the predicted affinity of CNT carriers toward the CD44 receptor (ΔScore ≈ -65 kcal mol-1). These results motivate experimental follow-up to confirm whether DDS2 can translate the in silico affinity gains into improved targeted delivery of platinum chemotherapeutics."

Journal • Oncology • CD44

Tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy with nimotuzumab in patients with stage IVA nasopharyngeal carcinoma: a retrospective study. (PubMed, Cancer Immunol Immunother) - "Tislelizumab plus induction chemotherapy followed by nimotuzumab with chemoradiotherapy significantly improved tumor response, superior progression-free survival, and manageable safety for high-risk LANPC. However, our study demonstrates the potential benefits of combining nimotuzumab with chemoradiotherapy after neoadjuvant chemotherapy in high-risk LANPC patients; the findings are preliminary and must be validated by larger, more rigorously designed trials."

Journal • Retrospective data • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Intraoperatively preventive intraperitoneal perfusion chemotherapy with lobaplatin in colorectal cancer: a prospective, randomised, controlled, multicentre study. (PubMed, BMC Med) - P4 | "Initiation of intraoperatively preventive intraperitoneal perfusion chemotherapy with lobaplatin reduced the 3-year PM rate in CRC patients while improving both 3-year RFS and PRFS. The treatment was well tolerated, and the safety findings were comparable with those of the control group."

Clinical • Journal • Colorectal Cancer • Oncology • Solid Tumor

Lobaplatin-based chemotherapy with immunotherapy as first-line treatment in patients with advanced NSCLC: A real-world bidirectional cohort study. (ASCO 2025) - P4 | "Previous phase III studies have confirmed a similar efficacy of lobaplatin /paclitaxel regimen to that of cisplatin/paclitaxel for Chinese advanced NSCLC patients...In 3D-bioprinted PDT models, LBP combined with tislelizumab achieved superior tumor suppression compared to the combination of CBP and tislelizumab, with lower IC50 values and reduced cell viability at Cmax concentrations... These findings suggest that the efficacy of lobaplatin was similar to carboplatin, and even safer when combined with ICIs in driver-gene-negative NSCLC. This study proposes a safer and feasible option for the first-line treatment for Chinese advanced NSCLC patients. Summary of AEs ≥10% of patients."

Clinical • IO biomarker • Metastases • Real-world • Real-world evidence • Immune Modulation • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • PD-1

Low-dose chemotherapy and pembrolizumab combined with radiotherapy in the first-line treatment of cT4b esophageal squamous cell carcinoma: A single-arm phase II study. (ASCO 2025) - "They received induction therapy consisting of 200mg nab-paclitaxel(NAB) and 30mg lobaplatin(LBP) and 200mg pembrolizumab on day 1 in each 21-day cycle for two cycles. Low-dose chemotherapy combined with pembrolizumab and radiotherapy demonstrated potential efficacy and well-tolerated safety profile as first-line treatment for cT4b ESCC. This trial is ongoing and warrants further exploration in ESCC."

Clinical • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Disorder • Infectious Disease • Oncology • Pneumonia • Respiratory Diseases • Squamous Cell Carcinoma • PD-L1

TACE combined with the intra-arterial infusion of bevacizumab for BCLC-stage B hepatocellular carcinoma beyond up-to-seven criteria: A prospective, single-arm, phase II study. (ASCO 2025) - P2 | "Patients were treated with TACE (30-40mg of pirarubicin, 30-40mg of lobaplatin, and lipiodol) plus Bevacizumab (15mg/kg, intra-arterial infusion, d1, Q3W) for four cycles, followed by maintenance therapy with Bevacizumab (15mg/kg, intravenously, d1, Q3W) to a maximum total cycle of eighteen unless any evidence of disease progression or unacceptable side effects. TACE combined with arterial infusion of bevacizumab in patients with BCLC-B stage HCC beyond up-to-seven criteria demonstrates promise as an effective treatment approach. Patient characteristics"

Clinical • P2 data • Hepatitis B • Hepatocellular Cancer • Hypertension • Infectious Disease • Oncology • Solid Tumor

Safety and efficacy analysis of neoadjuvant radiotherapy combined with concurrent paclitaxel plus nedaplatin versus other platinum-based chemotherapy for thoracic segmental esophageal squamous cell carcinoma. (PubMed, Front Oncol) - "A total of 212 patients were enrolled in this retrospective cohort study, including 79 who received NDP and 133 who received OPB (82 were treated with cisplatin, 20 with carboplatin, 19 with lobaplatin, and 12 with oxaliplatin) agents. The Kaplan-Meier curves for overall survival (OS) and progression-free survival (PFS) showed similar results for both groups. The safety profile of nedaplatin may be superior to those of other platinum-based agents in terms of acute radiotherapy toxicity and postoperative side effects; however, there was no difference in the efficacy between the two groups regarding short-term prognostic tumor regression grades or long-term OS and PFS."

Journal • Anorexia • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Disorder • Hematological Malignancies • Leukemia • Oncology • Pneumonia • Squamous Cell Carcinoma